Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. (Q31056138)

28 June 2017

title

Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. (English)

1 reference

28 June 2017

1 reference

Sylvie Villard

1

1 reference

28 June 2017

Dominique Piquer

2

1 reference

28 June 2017

Sanjee Raut

3

1 reference

28 June 2017

Jean-Paul Léonetti

4

1 reference

28 June 2017

Jean-Marie Saint-Remy

5

1 reference

28 June 2017

Claude Granier

6

1 reference

28 June 2017

language of work or name

English

0 references

publication date

14 May 2002

1 reference

Journal of Biological Chemistry

28 June 2017

published in

1 reference

28 June 2017

volume

277

1 reference

28 June 2017

issue

30

1 reference

28 June 2017

page(s)

27232-27239

1 reference

Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors).

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Epidemiology of inhibitors in haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Induction of tolerance using porcine factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Phage display technology: a tool to explore the diversity of inhibitors to blood coagulation factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

A priori delineation of a peptide which mimics a discontinuous antigenic determinant

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Affinity for the cognate monoclonal antibody of synthetic peptides derived from selection by phage display. Role of sequences flanking thebinding motif

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

DNA sequencing with chain-terminating inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

A simple method of studying the generation of thrombin in recalcified plasma; application in the investigation of haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

New monoclonal antibodies as probes for human cardiac troponin I: epitopic analysis with synthetic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Structure of the C2 domain of human factor VIII at 1.5 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

A synthetic mimic of a discontinuous binding site on interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M203415200

21 January 2018

Identifiers

DOI

10.1074/JBC.M203415200

1 reference

28 June 2017

1 reference